Clinical Trial: Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma

U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07129772) titled 'Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma' on Aug. 11.

Brief Summary: Nasopharyngeal carcinoma (NPC) is an endemic malignancy in Southern China and southeast Asia. Despite intensive radical therapy, between 15% and 30% of NPC patients develop relapse. Recent phase III randomized-controlled trials conducted in China demonstrated an improvement of progression-free survival with combinational therapy immune checkpoint inhibitors (ICI) (camrelizumab, toripalimab, and tislelizumab, respective) and chemotherapy gemcitabine (G) and cisplatin (P) compared with chemotherapy GP alone for recur...